Aska buys option to commercialize Pieris' potential EPO rival in Japan

By Gareth Macdonald

- Last updated on GMT


Related tags Erythropoietin

Aska Pharmaceutical Co. Ltd has bought an option to commercialize Pieris Pharmaceuticals’ anaemia candidate and EPO rival, PRS-080, in Japan.

The deal​ grants Aska the option to develop and commercialize the drug in Japan and other Asian markets.

Pieris was paid $2.75m (€2.59m) upfront for the option and stands to earn more than $80m in developmental and regulatory milestones if the option is exercised.

PRS-080 is a modified lipocalin protein that inhibits hepcidin, a polypeptide regulator of the iron metabolism. An excess of the protein in patients with kidney disease prevents iron uptake.

The idea is that PRS-080 is used to treat anaemia in kidney disease patients an alternative to current therapies like high dose erythropoietin stimulating medicines. 

A spokesman for Pieris told us PRS-080 is “produced in a high-quality E. coli expression system, which is cheaper than mammalian production​” adding the drug "is subsequently PEGylated for half-life extension​.”

CMO supply

At present PRS-080 is made on Pieris’ behalf by an unnamed contract manufacturing organisation (CMO). The contractor is likely to be supply Aska in the short term according to the spokesman.

Aska and Pieris will negotiate future supply arrangements during the ASKA option period but ASKA will be responsible for all costs related to drug supply in its territory and will also be responsible for its own market supply​” he said.

Pieris has completed dosing in a Phase Ib study​ in CKD patients on hemodialysis and will pursue a multi-dose, Phase IIa study in the same population, in the second half of 2017.

Related news

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more